New treatment options, such as ceftazidime/avibactam, meropenem/vaborbactam, ceftolozane/tazobactam, plazomicin, and eravacycline have become available.

Several antibiotics have been approved for the treatment of gram-negative bacterial infections, and clinical trials are underway that promise to provide ...

There are few newly commercialized drugs such as ertapenem and tigecycline that present activity against gram-negative rods, but at the mo- ment, old drugs such ...

The antibacterial spectrum of ceftazidime-avibactam makes ceftazidime-avibactam one of the first options for the empirical treatment of MDR, XDR, and CR/CP GN.

1 июл. 2012 г. · For infections with Gram-negative bacteria, antimicrobial synergy has traditionally been seen with β-lactam–aminoglycoside combinations. The ...

There is evidence supporting the initial use of combina- tion therapy for severe infections with Gram-negative bacteria, such as sepsis or ventilator-associated ...

Clinical features, diagnosis, and treatment of Klebsiella pneumoniae infection · Invasive liver abscess syndrome caused by Klebsiella pneumoniae · Microbiology ...

27 авг. 2022 г. · This study looks at the current and future effects of MDR Negative bacteria infections, current and potential treatment choices, and other aspects of the ...

Fluoroquinolones (FQs) remain the most commonly used oral antibiotic for GNBSI. Oral trimethoprim/sulfamethoxazole and β-lactams appear equally as efficacious ...